Intellia Therapeutics NTLA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -636.6%+15.1pp | -651.7%+180pp | -832.2%+137pp | -968.7%+219pp | -1,187.4%-264pp | |
| Net margin | -597%+12.8pp | -609.9%+165pp | -774.9%+134pp | -908.5%+246pp | -1,154.1%-257pp | |
| EBITDA margin | -622.2%+15.0pp | -637.2%+178pp | -814.8%+135pp | -949.5%+215pp | -1,164.8%-259pp | |
| Free cash flow margin | -550.2%+34.8pp | -585%+132pp | -717.3%+80.8pp | -798%+38.4pp | -836.4%-224pp | |
| Returns | ||||||
| Return on equity | -56.3%-2.9pp | -53.5%-1.4pp | -52.1%+4.8pp | -57%+1.0pp | -57.9%-3.9pp | |
| Return on assets | -45.2%-4.6pp | -40.6%+1.9pp | -42.5%+3.5pp | -45.9%+0.9pp | -46.8%-5.2pp | |
| Return on invested capital | -62.8%-4.1pp | -58.7%+1.3pp | -60%+3.7pp | -63.7%-1.7pp | -61.9%-3.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 6.1×+1.0× | 5.1×-1.1× | 6.2×+1.0× | 5.2×+0.3× | 4.9×-0.9× | |
| Quick ratio | 6.1×+1.0× | 5.1×-1.1× | 6.2×+1.0× | 5.2×+0.3× | 4.9×-0.9× | |
| Cash ratio | 1.8×+0.3× | 1.5×-0.6× | 2.1×+0.4× | 1.6×+0.5× | 1.1×-0.6× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.2×-0.1× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | |
| Per Share | ||||||
| Book value per share | $5.24-15.4% | $6.20-8.8% | $6.79-1.5% | $6.90-8.5% | $7.54-14.6% | |
| Valuation | ||||||
| Market capitalization | $1.51B+45.4% | $1.04B-43.8% | $1.85B+87.0% | $991.29M+34.7% | $736.01M-38.0% | |
| Enterprise value | $1.46B+49.1% | $979.18M-44.3% | $1.76B+87.5% | $937.71M+28.7% | $728.38M-39.7% | |
| Price / sales | 22.9×+7.5× | 15.4×-16.8× | 32.2×+13.5× | 18.8×+2.6× | 16.2×-4.4× | |
| Price / book | 2.4×+0.9× | 1.6×-0.9× | 2.5×+1.1× | 1.4×+0.4× | 0.9×-0.4× | |
| EV / sales | 22.1×+7.6× | 14.5×-16.1× | 30.6×+12.8× | 17.7×+1.8× | 16×-4.9× | |
| Free cash flow yield | -24%+14.0pp | -38%-15.8pp | -22.3%+20.3pp | -42.6%+9.2pp | -51.8%-21.9pp | |
| Earnings yield | -26.1%+13.6pp | -39.6%-15.6pp | -24%+24.4pp | -48.4%+23.0pp | -71.5%-27.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Intellia Therapeutics's ratios come from?
- Every ratio is computed from Intellia Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.